Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 361 to 370 of 864 total matches.

In Brief: Casgevy for Beta Thalassemia

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
-thalassemia. N Engl J Med 2021; 384:252. 4. F Locatelli et al. Exagamglogene autotemcel ...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based gene therapy recently approved for treatment of sickle cell disease1, has now been approved by the FDA for treatment of patients ≥12 years old with transfusion-dependent beta thalassemia. Casgevy is the first gene therapy that uses CRISPR/Cas9 gene-editing technology to be approved in the US for any disorder. Betibeglogene autotemcel (Zynteglo), an autologous lentiviral vector cell-based gene therapy, was approved in the US in 2022 for treatment of transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79   doi:10.58347/tml.2024.1702d |  Show IntroductionHide Introduction

Chemotherapy for Esophageal, Gastric and Colorectal Cancers

   
Treatment Guidelines from The Medical Letter • Aug 01, 2006  (Issue 48)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D., New York ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Treat Guidel Med Lett. 2006 Aug;4(48):55-60 |  Show IntroductionHide Introduction

Levocetirizine (Xyzal) for Allergic Rhinitis and Urticaria

   
The Medical Letter on Drugs and Therapeutics • Dec 03, 2007  (Issue 1275)
Chamber (VCC). Curr Med Res Opin 2004; 20:891. 12. F Horak et al. Levocetirizine has a longer duration ...
Levocetirizine (Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H1-antihistamine cetirizine (Zyrtec), has been approved by the FDA for treatment of seasonal and perennial allergic rhinitis (SAR and PAR) and chronic idiopathic urticaria in adults and children 6 years of age and older. Cetirizine has been approved by the FDA for over-the-counter use and may also become available generically in the US. Levocetirizine has been available in Europe since 2001.
Med Lett Drugs Ther. 2007 Dec 3;49(1275):97-9 |  Show IntroductionHide Introduction

Flutamide For Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 28, 1989  (Issue 797)
at the time of orchiectomy, if orchiectomy is preferred over use of leuprolide (F Labrie et al, J Steroid ...
Flutamide (Eulexin - Schering), an oral antiandrogen, is now available in the USA for treatment of metastatic prostate cancer. Flutamide is recommended by the manufacturer only for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron - Medical Letter, 27:71, 1985).
Med Lett Drugs Ther. 1989 Jul 28;31(797):72 |  Show IntroductionHide Introduction

Immunization of College Students Against Meningococcal Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000  (Issue 1084)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
The US Public Health Service Advisory Committee on Immunization Practices has recently published new recommendations for prevention and control of meningococcal disease in college students.
Med Lett Drugs Ther. 2000 Aug 7;42(1084):69 |  Show IntroductionHide Introduction

In Brief: Natalizumab (Tysabri) Withdrawn

   
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005  (Issue 1204)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
The February 14th issue of The Medical Letter reviewed natalizumab (Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in patients with multiple sclerosis. On February 28th, the FDA issued a Public Health Advisory announcing that marketing of the drug had been suspended because 2 patients who had been treated with natalizumab for more than 2 years had developed progressive multifocal leukoencephalopathy, a rare, often fatal disease...
Med Lett Drugs Ther. 2005 Mar 14;47(1204):21 |  Show IntroductionHide Introduction

In Brief: Elidel and Protopic

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005  (Issue 1205)
. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
The FDA issued a public health advisory on March 10, 2005 warning about a risk of cancer with topical formulations of tacrolimus (Protopic) and pimecrolimus (Elidel) used to treat eczema in adults and children more than 2 years old. Elidel has been heavily promoted to the general public on television. The warning was based on reports of dose-related cancer in animals and 29 reports of cancer (including 8 skin malignancies and 12 lymphomas) in adults and children treated with these immunosuppressive drugs. Cause and effect have not been established. When Protopic was first marketed, The Medical...
Med Lett Drugs Ther. 2005 Mar 28;47(1205):25 |  Show IntroductionHide Introduction

In Brief: Zegerid - Immediate-Release Omeprazole

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2005  (Issue 1206)
, M.D., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle ...
The FDA has approved marketing of Zegerid powder for oral suspension (Santarus), an immediate-release formulation of the proton-pump inhibitor (PPI) omeprazole (Prilosec, and others). All other oral PPIs are delayed-release, enteric-coated formulations designed to prevent degradation of the drug by gastric acid. Each 20- or 40-mg packet of Zegerid contains 1680 mg of sodium bicarbonate, which protects the drug from gastric acid degradation. A dose of Zegerid contains 460 mg of sodium, which may be excessive for some patients. Zegerid is the first oral PPI to be approved by the FDA for...
Med Lett Drugs Ther. 2005 Apr 11;47(1206):29 |  Show IntroductionHide Introduction

Drugs and Vaccines Against Biological Weapons

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 2001  (Issue 1115)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Elizabeth Stephens, M.D ...
Concerns have arisen anew about possible use of biological weapons. The pathogens considered most likely to be used for this purpose are discussed in this article. A good source for additional information is www.usamriid.army.mil/education/bluebook.html.
Med Lett Drugs Ther. 2001 Oct 15;43(1115):87-9 |  Show IntroductionHide Introduction

Voriconazole

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2002  (Issue 1135)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Elizabeth Stephens, M.D ...
Voriconazole (Vfend -- Pfizer), an antifungal triazole structurally related to fluconazole (Diflucan) with a spectrum of action similar to that of itraconazole, has been approved by the FDA for primary treatment of invasive aspergillosis and for refractory infection with Scedosporium apiospermum (the asexual form of Pseudallescheria boydii) or Fusarium spp.
Med Lett Drugs Ther. 2002 Jul 22;44(1135):63-5 |  Show IntroductionHide Introduction